ANIP: ANI Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ANIP: ANI Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,395.54
Enterprise Value ($M) 1,899.62
Book Value ($M) 428.53
Book Value / Share 21.10
Price / Book 3.26
NCAV ($M) -327.48
NCAV / Share -16.13
Price / NCAV -4.26

Profitability (mra)
Return on Invested Capital (ROIC) -0.02
Return on Assets (ROA) -0.02
Return on Equity (ROE) -0.04

Liquidity (mrq)
Quick Ratio 2.02
Current Ratio 2.72

Balance Sheet (mrq) ($M)
Current Assets 527.68
Assets 1,283.70
Liabilities 855.17
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 614.38
Operating Income 14.62
Net Income -18.52
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 64.02
Cash from Investing -404.72
Cash from Financing 264.94

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
6 days ago 13G/A Millennium Management Llc 3.80 -24.99
03-13 13D/A Meridian Venture Partners II GP, L.P. 5.40 -18.00
11-13 13G/A Rubric Capital Management LP 0.27 -94.96

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT UNDER SECTION
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT UNDER SECTION 13 O

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-15 56,588 147,709 38.31
2025-04-14 51,455 202,053 25.47
2025-04-11 86,525 249,315 34.71
2025-04-10 88,340 332,654 26.56

(click for more detail)

Similar Companies
ADMA – ADMA Biologics, Inc. AFMD – Affimed N.V.
ALT – Altimmune, Inc. APGE – Apogee Therapeutics, Inc.
APLT – Applied Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io